Decline depth
-49.8%
From rolling 252-day high of $24.28, 35d ago.
Past the 40% Red List threshold.
-49.8%
from rolling 252-day high of $24.28 set 2026-04-23 · 35d ago
Current
$12.20
Decline depth
-49.8%
Decline σ
1.1σ
TFC
1/5 bearish
Rolling 252-day high
Up day
Down day
Last 90 trading days · data from Alpaca
Since it joined the list
$ERAS landed on the list 2026-05-21, down 52.2% from its 52-week high that day — now down -49.8%.
It has clawed back 10.1 percentage points off that level. It bottomed 53.7% below that high along the way.
Decline from the 52-week high as it stood on 2026-05-21 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.
Structural break signals
ERAS qualifies for the Red List on decline depth.
Time-frame continuity
1/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3.
Decline sigma
1.1σ
Drop from local high over the last 5 bars, expressed in units of the stock's typical daily volatility (5.46% per day).
The structural read
What price action says about ERAS.
ERAS qualifies for the Red List on decline depth — down -49.8% from its rolling 252-day high. Past the 40% threshold, the deepest tier in the taxonomy. Depth plus recency: this is the pattern many investors call a falling knife.
Earnings on file: 2026-05-11. Tiering is unaffected by earnings dates — listings reflect price structure only.
52-week range
52W low $1.06
48.0% of range
52W high $24.28
Sector context · Healthcare
194 other Healthcare tickers are on Broken Stocks.
88
Red List
47
Amber
59
Watch
-35.8%
Median decline
Worst in sector: OPRX (-77.1%). Least-bad: MRNA (-20.1%). See all Healthcare listings →
Related — same sector
Closest decliners to ERAS
Red ListRecovering
CSTL
Castle Biosciences, Inc.
Red ListRecovering
KROS
Keros Therapeutics, Inc.
Red List
CVRX
CVRx, Inc.
Red ListRecovering
SPRY
ARS Pharmaceuticals, Inc.
Red List
ACET
Adicet Bio, Inc.
Red ListRecovering
VRDN
Viridian Therapeutics, Inc.
Questions about ERAS
What people ask.
Why is ERAS on Broken Stocks?
ERAS qualifies for the Red List on decline depth. It is down -49.8% from its rolling 252-day high of $24.28, set on 2026-04-23 — 35d ago.
Is ERAS a falling knife?
By the most common technical definition — a steep, recent breakdown from a fresh high — yes. ERAS is down -49.8% from its 52-week high of $24.28, set 35d ago. That combination of depth (past the 30% Amber threshold) and recency (high set inside the last 120 days) is the textbook falling-knife pattern. Whether to try to catch it is a separate question — historically most attempts to bottom-pick continue lower before reversing. Broken Stocks flags the pattern; it does not recommend buying or selling.
Is ERAS a buy?
Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.
Where is ERAS trading inside its 52-week range?
At $12.20, ERAS sits 48.0% of the way from its 52-week low ($1.06) to its 52-week high ($24.28). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.
How fast has ERAS been declining?
The current 49.8% decline accrued over 35d, which annualizes to roughly -519.3% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.
How does ERAS compare to its sector?
There are 194 other Healthcare tickers on Broken Stocks: 88 Red, 47 Amber, 59 Watch, with 108 showing recovering structural signals. Median sector decline is -35.8% — ERAS's decline is deeper than the sector median.
Does ERAS's earnings date affect its tier?
No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-05-11) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.